gdc
FDA Approvals, News & UpdatesLeukemiaNewsworthy

Besponsa a New Treatment Option for Patients with Relapsed/Refractory B-Cell ALL

December 2017 Vol 3 No 6

On August 17, 2017, the FDA approved the targeted therapy Besponsa (inotuzumab ozogamicin; from Pfizer) for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The drug blocks cancer growth by binding to B-cell ALL cells that express CD22.

“For adult patients with B-cell ALL whose cancer has not responded to initial treatment or has returned after treatment, life expectancy is typically low. These patients have few treatments available and today’s approval provides a new, targeted treatment option,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

This approval was based on a clinical trial that showed complete response to therapy with Besponsa in more than one-third of patients who received the drug. Serious side effects include liver toxicity, such as veno-occlusive disease or sinusoidal obstruction syndrome, as well as increased risk of death if used after certain stem-cell transplants.

Share this:

Recommended For You
CLL Monthly MinutesLeukemia
Treatment of Chronic Lymphocytic Leukemia During the COVID-19 Pandemic
The COVID-19 pandemic has resulted in several changes in how patients with chronic lymphocytic leukemia (CLL) are treated.
CLL Monthly MinutesLeukemia
From Watchful Waiting to Early Treatment of Asymptomatic Chronic Lymphocytic Leukemia
Better identification of patients at high risk of disease progression and newer treatments may mean that fewer newly diagnosed patients must “watch and wait.”
CLL Monthly MinutesLeukemia
Using Telemedicine to Protect Vulnerable Patients and Provide Access to Care During COVID-19
The use of telemedicine has shown rapid growth over the course of the pandemic, with some experts suggesting that it is here to stay.
CLL Monthly MinutesLeukemia
Studying the Effects of a “Can-Do” Attitude on Cancer Outcomes
Can a digital coach improve health outcomes in patients with blood cancers? An ongoing clinical trial should provide insights.
Last modified: January 2, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country